State AG Pulse Season 2 available now

News & Insights

  • Clear

Bipartisan AG Coalition Has Bone to Pick with Fosemax Preemption Ruling

A bipartisan coalition of 23 AGs filed a brief in the Third Circuit Court of Appeals in support of plaintiffs who allege they were harmed by the side effects of Fosemax, an osteoporosis drug. In their brief, the AGs argue the district court gave unduly sweeping preemptive effect to federal law when it found that…

Read More

“Lead Generation Loophole” Should be Targeted in Fight Against Illegal Robotexts, Say AGs

A bipartisan group of 28 AGs wrote a letter to the FCC in support of the Commission’s proposed efforts to combat illegal robotexts and robocalls. The letter supports the FCC’s proposal to extend Do-Not-Call Registry protections to robotexts, as well as its proposal to require wireless telecommunications companies to investigate and block the texts of…

Read More

ESG Battles Continue with Republican AG Info Requests to Major Asset Managers

Tennessee’s Republican AG Jonathan Skrmetti sent requests to ten major asset management firms asking them to provide information regarding how they seek to tackle climate change. The requests are part of an investigation into potential breaches of consumer protection laws through the promotion of environmental, social, and governance (ESG) investing practices. Skrmetti was part of…

Read More

EPA’s PFAS Drinking Water Rule Wins AG Support

A coalition of 17 AGs filed comments in support of an EPA proposal that would set enforceable national drinking water standards for six per- and polyfluoroalkyl substances (PFAS). The AGs’ comments emphasize that the residents of their states face substantial threats from PFAS and argue that the EPA has authority to set national standards for…

Read More

Suboptimal Suboxone Conduct Costs Indivior $102.5 Million

A group of 42 AGs settled with Indivior Inc. to resolve allegations that the pharmaceutical company violated the Sherman Act and state antitrust laws by engaging in anticompetitive activities to impede competition from generic equivalents of Suboxone, its brand-name opioid addiction treatment drug. Indivior was originally granted seven years of exclusivity to sell the Suboxone…

Read More